We proposed here a minimal physiologically based pharmacokinetic (mPBPK) model for a group of novel engineered antibodies in mice and humans. These antibodies are designed with altered binding properties of their Fc domain with neonatal Fc receptor (FcRn) or the Fab domain with their cognate targets (recycling antibodies) in acidic endosomes. To enable simulations of such binding features in the change of antibody pharmacokinetics and its target suppression, we nested an endothelial endosome compartment in parallel with plasma compartment based on our previously established mPBPK model. The fluid-phase pinocytosis rate from plasma to endothelial endosomes was reflected by the clearance of antibodies in FcRn dysfunctional humans or FcRn-knockout mice. The endosomal recycling rate of FcRn-bound antibodies was calculated based on the reported endosomal transit time. The nonspecific catabolism in endosomes was fitted using pharmacokinetic data of a human wild-type IgG 1 adalimumab in humans and B21M in human FcRn (hFcRn) transgenic mice. The developed model adequately predicted the pharmacokinetics of infliximab, motavizumab, and an Fc variant of motavizumab in humans and the pharmacokinetics of bevacizumab, an Fc variant of bevacizumab, and a recycling antibody PH-IgG 1 and its non-pH dependent counterpart NPH-IgG 1 in hFcRn transgenic mice. Our proposed model provides a platform for evaluation of the pharmacokinetics and disposition behaviors of Fc-engineered antibodies and recycling antibodies.
INTRODUCTION
Therapeutic monoclonal antibodies (mAbs), mostly based on immunoglobulin G (IgG), have become a group of fast-growing therapeutic modalities due to their long serum persistence and versatile target binding (1) . FcRn could protect IgG from lysosome degradation and contributes to its serum persistence (2) . Once taken up by endothelial cells via nonspecific fluid-phase pinocytosis along with other serum proteins, IgG is sorted to intracellular acidic endosomes where IgG can bind FcRn (3) . FcRn salvages bound IgG from lysosomal degradation and returns IgG to the cell surface where FcRn releases IgG back to circulation (3) . Because of FcRn salvage, IgG displays a long half-life (19-22 days) in humans (3) . Deficiency of functional FcRn, such as in rare familial hypercatabolic hypoproteinemia syndrome (4, 5) or in FcRn-knockout mice (6) , results in low plasma concentrations and short half-life of IgG.
The Fc portion of IgG can bind FcRn with a high affinity at acidic pH but with a relatively weak affinity at physiological pH (3, 7) . To improve the efficacy of IgG-based therapeutics, the Fc portion of IgG could be engineered to enhance IgG-FcRn binding affinity in the acidic endosomes so as to prolong IgG circulation and thereby reduce doses or dosing frequency (7) . However, each antibody molecule can, in theory, only neutralize one antigen molecule during its lifespan, regardless of its halflife and binding affinity (1) . When bound to a soluble target, the antibody, as well as the antibody-target complex, could be protected by FcRn from lysosomal degradation. Its cognate targets could also be protected along with the recycled antibodies, resulting in high antibody-mediated target accumulation (1) . Thereby, to neutralize targets of great abundance and fast turnover, high dose or dosing frequency is often required (1) . To prolong target neutralization and allow each antibody have multiple chances binding to its cognate targets, recycling Electronic supplementary material The online version of this article (https://doi.org/10.1208/s12248-017-0183-4) contains supplementary material, which is available to authorized users.
antibodies, antibodies with pH-dependent target binding have been developed (1, 8) . These engineered antibodies, with comparable target binding at physiological pH, can largely release its cognate targets in acidic endosomes during endosome recycling, which enables target lysosomal degradation and meanwhile saves the antibody for another round of target binding (1) .
To facilitate development of such novel engineered antibodies, we adapted our original mPBPK model by extending an endothelial endosome compartment in parallel with the plasma compartment, where the binding dynamics of antibody-FcRn and antibody-target are explicitly defined to enable mechanism-based predictions of the enhanced antibody half-life and target neutralization. This model can be potentially applied to guide the design of Fc-engineered or recycling antibodies, selection of therapeutic doses, and interspecies translations.
METHODS

Digitized Pharmacokinetic Data
Pharmacokinetic data for mAbs are digitized from the literature using WebPlot Digitizer v3.11 (Austin, TX): adalimumab (9) and infliximab (10) in rheumatoid arthritis (RA) patients, radiolabeled human IgG in a familial hypercatabolic hypoproteinemia patient (4), motavizumab and its YTE variant in healthy humans (11) , B21m in hFcRn Tg32 homozygous transgenic mice at a dose of 2 mg/kg (12), bevacizumab and its Xtend variant in hFcRn Tg276 heterozygous transgenic mice at a dose of 2 mg/kg (13) , and two human IgG 1 mAbs against human soluble interleukin 6 receptor (hsIL6-R) in hFcRn Tg32 homozygous transgenic mice, one pH-independent (NPH-IgG 1 ) and one pHdependent (PH-IgG 1 ) at a dose of 2 mg/kg (14) . hsIL6-R was co-injected at a dose of 50 μg/kg (14) . All antibodies and hsIL6-R were given intravenously.
Model Structure
Our previously published mPBPK model for mAbs inherited the essence of a full PBPK model by taking a reductionist approach to lump peripheral tissues into two groups based on their vascular structure and permeability (15, 16) . The tight tissues include muscle, skin, adipose, and brain. All the other organs are grouped as the leaky tissues. The mPBPK model has been successfully applied in the analysis of the pharmacokinetics and disposition features of many conventional mAbs (15, 16) . Here, we proposed to add an endothelial endosomal compartment that represents endosomes within the systemic vascular endothelial cells. The model structure is shown in Fig. 1 , where A, T, ATC, FcRnA, and FcRnATC represent free antibody, free soluble antigen target, antibodytarget complex, FcRn-antibody complex, and FcRn-antibodytarget complex, respectively. The model is described by differential Eqs. (1) to (15) . The subscripts p, 1, 2, L, and e stand for plasma, tight tissues, leaky tissues, lymph, and endosome, respectively. The definitions, values, and sources for the model parameters are summarized in Table I. In the model, ATC was assumed to follow the same disposition processes as A: intravenously administered antibody is distributed into peripheral tissues mainly through convection, limited in interstitial space, and recollected by lymphatic system back to plasma (15) . As many soluble targets (e.g., IL-β, TNF-α) in antibody therapeutics, tissue targets are assumed to be able to achieve instant distribution equilibrium with plasma targets provided their small sizes and high vascular permeability. For simplicity, only plasma clearance of target (CL p_T ) was defined in the model. The target is synthesized at a zero-order rate constant k syn , which is a product of antigen baseline concentration IC (C p_T ) and CL p_T .
Both antibodies and its cognate targets are taken up nonspecifically by pinocytosis from the plasma into the endothelial endosomal compartment at a rate of CL up . FcRnA and FcRnATC are recycled back to plasma at a rate of CL rec . A, T, and ATC are degraded in lysosomes at a rate of CL e . None endosome-independent clearance for antibody was considered as before (17) , while clearance of target is a sum of endosome-dependent clearance (CL up ) and endosome-independent clearance (CL p_T −CL up ) such as kidney filtration (for proteins smaller than the glomerular filtration cutoff of 70 kDa (18)). The dynamics of antibodytarget binding is characterized by association constant (k on ) and dissociation constant (k off ) in plasma, and association constant (k eon ) and dissociation constant (k eoff ) in endothelial endosomes. The dynamics of antibody-FcRn binding in acidic endosomes is characterized by association constant (k1 on ) and dissociation constant (k1 off ). ATC was assumed to have the same FcRn binding constants as free antibody and FcRnA has the same target binding affinity as free antibody.
Model Equations
Tight Tissues (V 1 )
Leaky Tissues (V 2 )
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Model Development and Simulation
The model was developed based on parameters that were either directly obtained from the literature or optimized by analyzing the digitized data. All parameters were summarized in Table I . The processes and results in optimization of several model parameters (CL up , CL rec , and CL e ) have been detailed in the BResults^section. The model was developed for both humans and mice, with species-specific physiological parameters. Once developed, the model was applied to predict the pharmacokinetics of a variety of engineered antibodies, as well as the dynamics of their cognate targets in both humans and mice. Simulations were performed using Berkeley Madonna v8.3.18 (Berkeley, CA). Model predictions were overlaid with experimental observations to evaluate model predictive performance. Exported data from Berkeley Madonna was plotted using GraphPad Prism v6.0 (La Jolla, CA).
RESULTS
Model Development for Humans
In our previous mPBPK model, the parameters specific to each mAb are σ 1 , σ 2 , and CL p (15, 16) . Here, we used the reported average σ 1 and σ 2 (16) in our previous paper (Table I ). In addition, we introduced three parameters to describe the kinetics of trafficking endosomes, including CL up , CL rec , and CL e . The nonspecific fluid-phase pinocytosis from plasma to endothelial endosomal space CL up in humans was estimated by multiplying the first-order rate constant of human IgG in a familial hypercatabolic hypoproteinemia patient (Fig. 2a, 0 .269 day −1 ) (4) with the volume of distribution at steady state (V ss ) of human wild-type IgG 1 adalimumab in humans (5.508 L) (19) . Because this patient lacks functional FcRn to recycle antibody back to the plasma (5), the elimination of antibody from the plasma is reflected in CL up . CL rec was calculated based on the endosomal transit half-life of 8 min (20) and the total volume of endosomal space in vascular endothelial cells, which is estimated as 0.005% of body weight (70 kg for human) (9) .
The systemic clearance (CL p_T ) of a soluble target, TNF-α, in RA patients was estimated according to the results in a clinical study of exogenous TNF-α in tumor patients (half-life 13 min was used) (21) . The zero-order synthesis rate (k syn ) of TNF-α in 70 kg human was calculated as a product of reported baseline concentration in RA patients (22) and CL p_T . Non-endosome-mediated clearance of antigen was calculated by subtracting CL up from CL p_T . Adalimumab and FcRn binding in endothelial endosomes and adalimumab and TNF-α binding in plasma were characterized by literature reported association constants and dissociation constants, which were both measured by surface plasmon resonance (Table II) . We assumed that the binding affinity of adalimumab to TNF-α in acidic endosomes was equal to the binding affinity at pH 7.4, given that adalimumab was not engineered to display pH-dependent target binding.
With the developed model and literature-derived parameters (Tables I and II) , CL e was obtained by fitting the pharmacokinetic data of adalimumab in RA patients at a dose of 5 mg/kg (9). The model was then applied to predict the pharmacokinetic profiles of adalimumab at four other doses. As shown in Fig. 2b , the model sufficiently predicted the pharmacokinetic profiles of adalimumab at all dose levels.
Predictions of Infliximab Pharmacokinetics in RA Patients
We tested if the model can characterize the pharmacokinetics of another anti-TNF-α antibody with distinct target and FcRn binding properties. Infliximab is a chimeric IgG 1 against TNF-α. We parameterized the model with the reported FcRn and TNF-α binding kinetic parameters for infliximab (Table II) . Figure 3 shows the overlap of observed and model predicted pharmacokinetic profiles of infliximab in RA patients. The developed model adequately predicted the pharmacokinetic profiles of infliximab at doses between 5 and 20 mg/kg.
Predictions of Motavizumab and Its Fc Variant Pharmacokinetics in Healthy Humans
We tested if the model can predict the extended circulation of a Fc-engineered variant of motavizumab in healthy humans. Motavizumab is a human IgG 1 against respiratory syncytial virus. A motavizumab variant with mutations in three amino acids (M252Y/S254T/T256E
[YTE]) in the Fc region, referred to as YTE, showed 10-fold higher FcRn binding affinity at pH 6 with extended halflife in non-human primates and humans (11, 23) . The same FcRn binding constants were assumed for motavizumab and adalimumab considering both antibodies are human IgG 1 wild type. As YTE is known with 10-fold higher affinity than motavizumab in acidic endosomes, 0.1 × ke off was assumed for YTE (Table II) . As shown in Fig. 4 , the model predictions agreed well with the observed pharmacokinetics of motavizumab and YTE in healthy subjects at doses of 0.3, 3, 15, and 30 mg/kg.
Model Development for hFcRn Transgenic Mice
hFcRn transgenic mice have become a common preclinical model for pharmacokinetic study of mAbs (24, 25) . To enable simulations in hFcRn transgenic mice, the same model was updated with mouse-specific physiological parameters (Table I) . Most parameters were obtained from the literature. Similarly to human model, we estimated the CL up in mice using the reported clearance of a murine IgG 1 7E3 in FcRn knockout mice (72.5 mL/day/kg) (26) . CL e was optimized using the pharmacokinetic data of a human wild-type IgG 1 B21M in hFcRn Tg32 homozygous transgenic mice ( Fig. 5 and Table I ).
Predictions of Bevacizumab and Its Fc Variant Pharmacokinetics in hFcRn Transgenic Mice
Bevacizumab is a humanized anti-VEGF IgG 1 for treatment of colorectal, lung, breast, and renal cancers (13) . A double-substituted Fc variant of bevacizumab, which was referred to as Xtend, exhibited decreased hFcRn equilibrium dissociation constant at pH 6 from 2460 to 218 nM (13) . Parameterizing the mice model with the reported hFcRn binding kinetics for bevacizumab and Xtend (Table II) , the model successfully predicted the extended circulation half-life of Xtend in comparison to bevacizumab in hFcRn Tg276 heterozygous transgenic mice (13) (Fig. 6 ).
Predictions of a Recycling Antibody in hFcRn Transgenic Mice
The model has shown to adequately predict the extended pharmacokinetic profiles of Fc-engineered antibodies in both humans and hFcRn transgenic mice. Next, we tested if our model could capture the benefit of a recycling antibody PHIgG 1 in target suppression in comparison to its pHindependent counterpart NPH-IgG 1 . Both antibodies were co-injected with the human antigen hsIL6-R into hFcRn Tg32 homozygous transgenic mice (14) . These two antibodies exhibited similar plasma profiles. As designed, the recycling antibody resulted in much lower target plasma concentrations, indicating less antibody-mediated target accumulation and that antibody-bound antigens could be largely dissociated in endosomes for subsequent lysosomal degradation.
Prediction of hsIL6-R profiles in hFcRn transgenic mice was conducted similarly to the TNF-α case in humans. Since each antibody binds two hsIL6-R (14), the target concentration was divided by two in the model equations. Systemic clearance of free target was obtained from a pharmacokinetic study in healthy mice (8) . This clearance was divided into endosome-dependent clearance (CL up ) and endosomeindependent clearance (CL p_T −CL up ). We assumed that none antigens were released from antibody-antigen complex in endosomes for NPH-IgG 1 , while all antigens became unbound for PH-IgG 1 . Target dissociation constant in endosomes was assigned 0 (no dissociation) for NPH-IgG 1 and an artificial high value 1000 day −1 for pH-IgG 1 (full dissociation). The target association constants in endosomes for both antibodies were set equal to those measured at pH 7.4 (14) . As shown in Fig. 7 , the model was able to recapture the enhanced antigen clearance of PH-IgG 1 in comparison to its non-pH dependent counterpart NPH-IgG 1 . Unexpectedly, the model under-predicted the terminal concentration of antigen for NPH-IgG 1 , which might be due to a saturable mechanism that significantly retained the targets at low concentrations, which was not included in our model assumptions. The terminal half-life of hsIL6-R (37.8 kDa) in healthy mice was reported to be 4.36 h (8), much longer than the half-life of another small protein TNF-α (17 kDa, 3 min in mice (27) ).
Theoretical Simulations of Engineered Antibodies with Enhanced FcRn Binding and pH-Dependent Target Binding
The effect of enhanced FcRn binding at acidic environment on the pharmacokinetics of adalimumab and circulating TNF-α were simulated in RA patients by up-adjusting the association constant or down-adjusting the dissociation constant up to 1000-fold. As shown in Fig. 8a , b, plasma concentrations of free adalimumab were increased and plasma concentrations of free TNF-α were decreased accordingly. An increase of the association constant to FcRn has almost equivalent effect as a decrease of the same fold of dissociation constant on the plasma profiles of adalimumab and circulating TNF-α.
The effect of reduced target binding in acidic endosomes on clearance of adalimumab and TNF-α was also simulated. In contrast to FcRn binding, TNF-α suppression showed a dramatic difference between the decrease of association rate and increase of dissociation rate. As shown in Fig. 8c, d , increase of the dissociation constant k eoff was more effective on target suppression than decrease of the association constant ke on . Predicted plasma profiles of free adalimumab remained the same regardless of target binding rate constants.
DISCUSSION
We developed an mPBPK model extended with an endothelial endosome compartment to enable simulations of newly developed novel antibodies that are engineered to modify either FcRn or target binding properties in acidic endosomes. The endosome compartment represented the endosomal spaces within systemic vascular endothelial cells (28) , which was thereby nested in parallel with the plasma compartment instead of inside the peripheral tissue compartments. Antibody transportation into the endothelial endosome compartment was assumed to negligibly contribute to the peripheral distribution of antibodies and all FcRn-bound antibodies would be recycled back to plasma. This assumption is supported by the fact that the endosomal transit is much faster (half-life 8 min (20)) than the peripheral distribution of mAbs and the amount of mAbs in the tiny volume of endosomes is not significant at any moment of time in comparison to the total amount of antibody in the system (15, 29) . This is also supported by the results of Ng et al. showing that the model performance would decrease if the endosome compartment were nested within the tissue compartment of a two-compartment mammary model (29) . Thus, the endosome compartment was incorporated in parallel with the plasma compartment in our extended mPBPK model to account for catabolism of mAbs insides endothelial cells. Additionally, our model is developed based on the following assumptions: (1) Antibody-target complex follows the same distribution kinetics as free antibody, including same pinocytosis rate into endothelial endosomes, equal vascular reflection coefficients, and no additional targetmediated degradations. (2) Binding to target does not interfere with the binding kinetics of antibody to FcRn. (3) All FcRn-bound antibodies could be recycled back to plasma. (4) All free antibody, antibody-target complex, and antigens are trapped in late endosomes for subsequent lysosomal degradation. These model assumptions limited the current model mainly applied to engineered antibodies for soluble targets not for simulations of trans-membrane targets. Antibodies for trans-membrane targets are often known to elicit target-mediated endocytosis and degradation, also known as target-mediated drug disposition. Transmembrane targets are often involved in tissue (or cells) specific pinocytosis and degradation other than the universal nonspecific pinocytosis for antibodies and soluble targets in our current model assumption. In addition, the values of CL up were obtained based on the clearance of wild-type IgG in FcRn-deficient human and mice. The current CL up values would not support precise predictions of the pharmacokinetics of antibodies that have appreciable differences than wild-type IgG. Influence by strong charge-mediated nonspecific binding or charge-induced endocytosis should be specifically considered in order to define an antibody specific CL up . Endogenous IgG was also not considered in Majority of the model parameters were either directly obtained in the literature or derived from literature data. Only parameter CL e was model optimized using the pharmacokinetic data of a human wild-type IgG 1 adalimumab for humans and B21M for hFcRn transgenic mice. The developed model successfully predicted the pharmacokinetics of adalimumab and infliximab, which have distinct FcRn and TNF-α binding properties. The CL e value for mice is 9.8-fold lower than the allometric scaled value from 70 kg humans (use allometric exponent 0.75). This difference may be partly attributed to inaccurate estimations of FcRn expression and lack of quantitative knowledge in the endosome trafficking and degradation in humans and hFcRn transgenic mice. Nonetheless, the model for hFcRn transgenic mice well predicted the pharmacokinetics of bevacizumab and its Fcengineered Xtend variant and adequately captured the plasma profiles of a recycling antibody and its target in hFcRn transgenic mice.
In predictions of the pharmacokinetics of motavizumab and its YTE variant in humans, we found that when adjusting CL e from 0.24 L/h to a lower value 0.069 L/h, the pharmacokinetic profiles of motavizumab and YTE could be also reproduced with a calculated k1 off based on reported K D values (23) for both antibodies and k1 on assumed as the same as our model IgG 1 adalimumab (supplemental 1). This might be associated with either the population difference (RA patients vs. healthy humans), or the drift of surface plasmon resonance measurements at different experimental settings (33, 34) . Regardless, with another source of FcRn binding parameters, our extended mPBPK model could well predict the plasma profiles of motavizumab and YTE by only adjusting CL e to a lower value. Correlation between FcRn binding affinity and lysosomal degradation has also been reported by others (28, 29) , highlighting the importance of accurate and consistent measurements of FcRn binding affinity in predictions of antibody pharmacokinetics.
Indeed, antibody half-life predicted by the model is a function of FcRn expression, FcRn binding affinity, CL up , CL rec , and CL e , where CL up and CL rec could be estimated based on the data in FcRn knockout mice (26) and using data from in vitro endocytosis studies (20) . The FcRn expression, FcRn binding affinity, and CL e are parameters that are inter-reliant in prediction of antibody half-life, but the precise values of these parameters are not readily obtainable from the literature, particularly in the absence of accurately measured antibodyFcRn binding constants. Herein, the developed modeling platform aims mainly to provide theoretical assessments of the design benefit of novel engineered antibodies in comparison to their wild-type counterparts. In this model, we assumed the mFcRn expression level was 40 μM in wild-type mice (30) and the same level of FcRn was assumed in hFcRn transgenic mice. B21M showed similar half-life in Tg32 homozygous, Tg32 heterozygous, and Tg276 homozygous mice and slightly shorter half-life in Tg276 heterozygous mice (12) , which implied that the former three lines may have higher hFcRn expressions than the latter. Once more accurate measurements of FcRn expression are available, the model could be advanced to consider specific mice strain.
Our model simulations support that enhanced FcRn pH-dependent binding can efficiently extend mAb half-life and augment target suppression. The FcRn binding affinity could be enhanced by either increase of association constant or decrease of dissociation constant. Of note, the additional benefit by an increase in the FcRn binding affinity gradually decreased and reached a plateau once most antibodies in the endosomes bound to FcRn. One assumption in our model that endosomal antibody degradation (CL e ) and FcRn binding affinity remained unchanged after bound to its cognate target is supported by the observed similar clearance of NPH-IgG 1 and PH-IgG 1 (14) . As designed, recycling antibody, which could effectively dissociate its cognate targets during endosome trafficking, exhibits dramatic benefit in target suppression. The higher benefit was noticed by increase of the target dissociation constant than decrease of the association constant. This is mainly because the target is present primarily in the antibody-bound form in endothelial endosomes (supplemental 2), and hence the degradation of antigens in endosomes is primarily constrained by its dissociation rate. A 10-fold stepwise increase of the dissociation constant shortened the target dissociation half-life from 89 to 8.9 min (10-fold), 0.89 min (100-fold), and 0.089 min (1000-fold). The largest change in target suppression was noticed when the dissociation half-life was modified from 8.9 to 0.89 min, suggesting that dissociation half-life would have a significant impact on target suppression when it approximates to endosomal transit time. If the antibody target dissociation half-life in endothelial endosomes is much higher than endosomal transit half-life, more vigorous modulations of the antibody-target binding in endosomes are warranted.
CONCLUSIONS
In this study, we developed an mPBPK model extended with an endothelial endosome compartment to enable explicit characterizations of the binding kinetics of antibody to FcRn and antibody to its cognate targets. The model has been applied to adequately reproduce the pharmacokinetics of novel engineered antibodies with altered FcRn or target binding profiles in acidic endosomes. This model has demonstrated high potential to guide the design of Fc-engineered or recycling antibodies, simulations of the designed benefits, and interspecies translations.
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